---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-25-000065"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:04:36.840165+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B

## Summary
- Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.
- Combined addressable market grows from $1B to $5B; company expects accelerated path to profitability by 2026.
- CEO Masoud Toloue and CFO Vandana Sriram continue; new board members Scott Mendel and Myla Lai-Goldman appointed.
- Prior directors Martin Madaus and Sarah Hlavinka resigned effective at closing; cash balance ~$163M post-transaction.
- Historical financials of Akoya and pro forma financials to be filed within 71 days via 8-K/A.

## SEC filing metadata
- accession: 0001503274-25-000065
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000065/0001503274-25-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000065/qtrx-20250708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-25-000065
- JSON: https://secwatch.observer/filing/0001503274-25-000065.json
- Plain text: https://secwatch.observer/filing/0001503274-25-000065.txt

## Key facts
- M&A Transactions
  Quanterix Corp completed an acquisition involving Akoya Biosciences, Inc. for approximately 7.8 million shares of its common stock and paid approximately $20 million in cash (closed 2025-07-08).
  - Action: acquisition
  - Counterparty: Akoya Biosciences, Inc.
  - Consideration: approximately 7.8 million shares of its common stock and paid approximately $20 million in cash
  - Closing: 2025-07-08
  source text: Effective Time and (ii) the aggregate Per Share Cash Consideration paid by the Company in connection with the transactions contemplated in the Merger Agreement does not exceed $20,000,000. The foregoing summary of the Merger Agreement and the Merger is not complete and is qualified in its entirety by reference to the complete text of the Merger Agreement, which is
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000065/0001503274-25-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.